$STOK News

Last published 1w ago

1w agoSTOKThird Quarter 2026 Business and Financial Update - STOKE THERAPEUTICS INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to Stoke Therapeutics' 3rd Quarter 2026 Business Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there w
1w agoSTOKStoke Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoSTOK BIIBStoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business UpdatesBusiness Wire–Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome: ~110 patients through Week 28 primary endpoint, ~20 patients through Week 52 and all continuing into open-label treatment period;
2w agoSTOK BIIBStoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial UpdatesBusiness WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
3w agoSTOKStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
1mo agoSTOKStoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual MeetingBusiness Wire–ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in insufficient levels of OPA1 protein, leading to progressive and irreversible vision
1mo agoSTOKStoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual MeetingBusiness Wire–ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in insufficient levels of OPA1 protein, leading to progressive and irreversible vision
1mo agoSTOK BIIBStoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet SyndromeBusiness Wire– Analysis of the Phase 3 EMPEROR key secondary endpoint of changes in cognition and behavior will be performed using a multicomponent assessment of four Vineland-3 subdomains – – Phase 3 readout anticipated in the
1mo agoSTOK BIIBStoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and CommercializationBusiness Wire–Mr. Cumbo brings deep experience commercializing new medicines for people with rare genetic diseases– –Company announces retirement of Director Edward Kaye, M.D., from the Board– Stoke Therapeutics, Inc.
1mo agoSTOKStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
2mo agoBIIB STOKStoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)GlobeNewswire–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on
2mo agoSTOK BIIBStoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)Business Wire–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on
2mo agoSTOK BIIBStoke Therapeutics to Present at the Cantor Global Healthcare ConferenceBusiness WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
2mo agoSTOK BIIBStoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)Business Wire–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– –Improvements in cognition and behavior sustained through 4 years, in addition to
2mo agoBIIB STOKStoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)GlobeNewswire–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– –Improvements in cognition and behavior sustained through 4 years, in addition to
2mo agoSTOKStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
3mo agoSTOKCG 46TH ANNUAL GROWTH CONFERENCE - STOKE THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone. I'm Samanth Kulkarni, a Senior Biotechnology Analyst at Canaccord Genuity, and I'm really pleased to have Stoke Therapeutics with us here today. Thankfully, we didn't have to travel too far, but I
3mo agoSTOKCG 46TH ANNUAL GROWTH CONFERENCE - STOKE THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone. I'm Samanth Kulkarni, a Senior Biotechnology Analyst at Canaccord Genuity, and I'm really pleased to have Stoke Therapeutics with us here today. Thankfully, we didn't have to travel too far, but I
3mo agoSTOK BIIBStoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth ConferenceBusiness WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
3mo agoSTOK BIIBStoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business UpdatesBusiness Wire– Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data readout anticipated in Q3 2027 – – Pre-NDA meeting with FDA scheduled for H2 2026; rolling U.S. NDA submission
3mo agoSTOK BIIBStoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial UpdatesBusiness WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
3mo agoSTOKStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
4mo agoSTOK BIIBStoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific OfficerBusiness Wire–Dr. McCauley brings more than 25 years of experience building high-performing R&D organizations and translating early scientific discoveries into new medicines for people with severe diseases– Stoke
4mo agoSTOK BIIBStoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet SyndromeBusiness Wire—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027— —Phase 3 data readout anticipated in the third quarter of 2027 to complete the rolling U.S. NDA submission in the
4mo agoSTOKStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
5mo agoSTOKStoke Therapeutics, Inc. Jefferies Global Healthcare Conference in New York - STOKE THERAPEUTICS INCEarnings Call TranscriptsOkay, we're gonna get started with our next session. I'm Andrew Tsai, senior biotech analyst at Jefferies. Thanks for joining us today. And it's my pleasure to have the Stoke team with me. To my direct left, Ian Smith, C
5mo agoBIIB STOKStoke Therapeutics to Present at Upcoming Investor Conferences in JuneBusiness WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
5mo agoSTOKStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
6mo agoBIIB STOKStoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdatesBusiness Wire– New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the disease-modifying potential of zorevunersen, an investigational medicine for the treatment of
6mo agoBIIB STOKStoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial UpdatesBusiness WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
6mo agoSTOKStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
7mo agoBIIB STOKStoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
7mo agoANVS ARQT AVAI NTLA+1The Credibility Filter Wall Street Uses to Sort Biotech WinnersGlobeNewswireVANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid
7mo agoBIIB STOKStoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of DirectorsBusiness WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
7mo agoSTOKStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
8mo agoBIIB STOKThe New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet SyndromeBusiness Wire–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ongoing global Phase
8mo agoBIIB STOKThe New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet SyndromeGlobeNewswire–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ongoing global Phase 3
8mo agoBIIB STOKStoke Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferenceBusiness WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
8mo agoSTOKStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
9mo agoSTOKStoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)Business Wire–Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA– –Changes in visual function, ocular structure and quality of life to be evaluated as secondary
9mo agoBIIB STOKStoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026Business WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
9mo agoSTOKAnchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MAPR NewswireAnchor Line Partners, LLC and Northwood Investors, LLC announced today that they have secured a significant long-term lease with biotechnology...
10mo agoSTOKStoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
11mo agoSTOKStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
11mo agoBIIB STOKBiogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual MeetingGlobeNewswire—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in
11mo agoBIIB STOKStoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual MeetingBusiness Wire—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in
11mo agoBIIB STOKStoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual MeetingBusiness Wire– New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potential for disease
11mo agoBIIB STOKBiogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual MeetingGlobeNewswireCAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by
11mo agoSTOKStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in
11mo agoBIIB STOKBiogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral ImpairmentsGlobeNewswire– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with